Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.63)
# 195
Out of 5,090 analysts
140
Total ratings
51.22%
Success rate
43.75%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $33 → $42 | $29.91 | +40.42% | 2 | Dec 1, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $30 → $40 | $26.69 | +49.87% | 2 | Nov 21, 2025 | |
| NUVB Nuvation Bio | Initiates: Buy | $12 | $8.55 | +40.35% | 1 | Nov 19, 2025 | |
| NVAX Novavax | Reiterates: Buy | $18 → $16 | $6.91 | +131.55% | 20 | Nov 10, 2025 | |
| CYTK Cytokinetics | Reiterates: Buy | $80 → $90 | $65.67 | +37.05% | 5 | Nov 10, 2025 | |
| HROW Harrow | Reiterates: Buy | $70 → $74 | $45.75 | +61.75% | 4 | Oct 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $460 → $560 | $577.30 | -3.00% | 13 | Sep 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $85 → $105 | $56.90 | +84.53% | 3 | Sep 23, 2025 | |
| TGTX TG Therapeutics | Maintains: Buy | $53 → $55 | $30.76 | +78.80% | 14 | Sep 17, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $28 | $18.55 | +50.94% | 1 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.35 | +172.11% | 1 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $18 | $5.24 | +243.51% | 10 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.56 | +220.51% | 2 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $3 | $1.37 | +118.98% | 2 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2.5 → $2 | $0.36 | +454.02% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 → $20 | $13.47 | +48.48% | 3 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.72 | +74.42% | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 → $35 | $19.96 | +75.35% | 2 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $51 → $38 | $61.44 | -38.15% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $109 → $96 | $38.55 | +149.03% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1 → $1.5 | $1.73 | -13.29% | 3 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $19.15 | +631.07% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $90 | $3.98 | +2,161.31% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.93 | +3,971.25% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $3.85 | +29.87% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $3.19 | +1,279.31% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $2.83 | +3,080.21% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $1.91 | +266.49% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $1.25 | +359,900.00% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5,000 → $2,700 | $1.58 | +170,786.08% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $7.13 | +979.94% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $1.12 | +128,471.43% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $5.74 | -30.31% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $92.20 | -57.70% | 2 | Mar 18, 2020 |
Centessa Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $33 → $42
Current: $29.91
Upside: +40.42%
Zymeworks
Nov 21, 2025
Reiterates: Buy
Price Target: $30 → $40
Current: $26.69
Upside: +49.87%
Nuvation Bio
Nov 19, 2025
Initiates: Buy
Price Target: $12
Current: $8.55
Upside: +40.35%
Novavax
Nov 10, 2025
Reiterates: Buy
Price Target: $18 → $16
Current: $6.91
Upside: +131.55%
Cytokinetics
Nov 10, 2025
Reiterates: Buy
Price Target: $80 → $90
Current: $65.67
Upside: +37.05%
Harrow
Oct 1, 2025
Reiterates: Buy
Price Target: $70 → $74
Current: $45.75
Upside: +61.75%
Madrigal Pharmaceuticals
Sep 29, 2025
Maintains: Buy
Price Target: $460 → $560
Current: $577.30
Upside: -3.00%
Nektar Therapeutics
Sep 23, 2025
Maintains: Buy
Price Target: $85 → $105
Current: $56.90
Upside: +84.53%
TG Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $53 → $55
Current: $30.76
Upside: +78.80%
Theravance Biopharma
Sep 12, 2025
Initiates: Buy
Price Target: $28
Current: $18.55
Upside: +50.94%
Aug 26, 2025
Initiates: Buy
Price Target: $20
Current: $7.35
Upside: +172.11%
Aug 13, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $5.24
Upside: +243.51%
Jun 16, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $1.56
Upside: +220.51%
May 20, 2025
Maintains: Neutral
Price Target: $5 → $3
Current: $1.37
Upside: +118.98%
Mar 27, 2025
Maintains: Buy
Price Target: $2.5 → $2
Current: $0.36
Upside: +454.02%
Mar 19, 2025
Reiterates: Buy
Price Target: $11 → $20
Current: $13.47
Upside: +48.48%
Mar 14, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $1.72
Upside: +74.42%
Mar 5, 2025
Reiterates: Buy
Price Target: $38 → $35
Current: $19.96
Upside: +75.35%
Feb 14, 2025
Reiterates: Buy
Price Target: $51 → $38
Current: $61.44
Upside: -38.15%
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $38.55
Upside: +149.03%
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $1.73
Upside: -13.29%
Oct 13, 2023
Initiates: Buy
Price Target: $140
Current: $19.15
Upside: +631.07%
Apr 10, 2023
Maintains: Buy
Price Target: $210 → $90
Current: $3.98
Upside: +2,161.31%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.93
Upside: +3,971.25%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $3.85
Upside: +29.87%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $3.19
Upside: +1,279.31%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $2.83
Upside: +3,080.21%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $1.91
Upside: +266.49%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $1.25
Upside: +359,900.00%
Nov 30, 2021
Maintains: Buy
Price Target: $5,000 → $2,700
Current: $1.58
Upside: +170,786.08%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $7.13
Upside: +979.94%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $1.12
Upside: +128,471.43%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $5.74
Upside: -30.31%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $92.20
Upside: -57.70%